Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for
May 10, 2018, 4:30 p.m. ET
CORALVILLE, Iowa, May 01, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2018.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 3649247
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast and presentation will remain available for 90 days beginning at approximately 5:30 p.m. ET, on May 10, 2018.
About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition, the company has received FDA approval for APADAZ™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both APADAZ and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.
| Investor Contacts: | Media Contact: |
| Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] | Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected] |
